Trial reportPloS one2015
Vitamin D₃supplementation in Batswana children and adults with HIV: a pilot double blind randomized controlled trial.
Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02189902 (Botswana Vitamin D Supplementation Study in HIV/AIDS), which is not on this map. Cited by 21 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Botswana Vitamin D Supplementation Study in HIV/AIDS
Who cites it
21 citing papers in PubMed, 5 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- The health outcomes of vitamin D supplementation in Africa: a systematic review and meta-analysis.BMC nutrition · 2025Pooled it
- Association of vitamin D with HIV infected individuals, TB infected individuals, and HIV-TB co-infected individuals: a systematic review and meta-analysis.Frontiers in public health · 2024Pooled it
- Pooled it
- Micronutrient supplementation in adults with HIV infection.The Cochrane database of systematic reviews · 2017Pooled it
- Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data.BMJ (Clinical research ed.) · 2017Pooled it
- Effects of cholecalciferol supplementation on serum and urinary vitamin D metabolites and binding protein in HIV-infected youth.The Journal of steroid biochemistry and molecular biology · 2017Trial
- TDF and quantitative ultrasound bone quality in African patients on second line ART, ANRS 12169 2LADY sub-study.PloS one · 2017Trial
- High dose dietary vitamin D allocates surplus calories to muscle and growth instead of fat via modulation of myostatin and leptin signaling.Research square · 2024Article
- Vitamin D deficiency and oral candidiasis in patients with HIV infection: A case‒control study.BMC infectious diseases · 2024Article
- Effect of high dose vitamin DJournal of virus eradication · 2023Article
- Review
- The role of baseline serum 25(OH)D concentration for a potential personalized vitamin D supplementation.European journal of clinical nutrition · 2022Article
- Low bone mass in people living with HIV on long-term anti-retroviral therapy: A single center study in Uganda.PloS one · 2021Article
- Vitamin D status, nutrition and growth in HIV-infected mothers and HIV-exposed infants and children in Botswana.PloS one · 2020Article
- Article
- The Potential Protective Role of Vitamin D Supplementation on HIV-1 Infection.Frontiers in immunology · 2019Review
- Continued Interest and Controversy: Vitamin D in HIV.Current HIV/AIDS reports · 2018Review
- Vitamin D in pediatric age: consensus of the Italian Pediatric Society and the Italian Society of Preventive and Social Pediatrics, jointly with the Italian Federation of Pediatricians.Italian journal of pediatrics · 2018Review
- A pilot validation study of crowdsourcing systematic reviews: update of a searchable database of pediatric clinical trials of high-dose vitamin D.Translational pediatrics · 2017Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
Abstract
objectivesSince vitamin D insufficiency is common worldwide in people with HIV, we explored safety and efficacy of high dose cholecalciferol (D₃) in Botswana, and evaluated potential modifiers of serum 25 hydroxy vitamin D change (Δ25D).
designProspective randomized double-blind 12-week pilot trial of subjects ages 5.0-50.9 years.
methodsSixty subjects randomized within five age groups to either 4000 or 7000 IU per day of D₃ and evaluated for vitamin D, parathyroid hormone, HIV, safety and growth status. Efficacy was defined as serum 25 hydroxy vitamin D (25D) ≥32 ng/mL, and safety as no simultaneous elevation of serum calcium and 25D. Also assessed were HIV plasma viral RNA viral load (VL), CD4%, anti-retroviral therapy (ART) regime, and height-adjusted (HAZ), weight-adjusted (WAZ) and Body Mass Index (BMIZ) Z scores.
resultsSubjects were 50% male, age (mean±SD) 19.5±11.8 years, CD4% 31.8±10.4, with baseline VL log₁₀ range of <1.4 to 3.8 and VL detectable (>1.4) in 22%. From baseline to 12 weeks, 25D increased from 36±9 ng/ml to 56±18 ng/ml (p<0.0001) and 68% and 90% had 25D ≥32 ng/ml, respectively (p = 0.02). Δ25D was similar by dose. No subjects had simultaneously increased serum calcium and 25D. WAZ and BMIZ improved by 12 weeks (p<0.04). HAZ and CD4% increased and VL decreased in the 7000 IU/d group (p<0.04). Younger (5-13y) and older (30-50y) subjects had greater Δ25D than those 14-29y (26±17 and 28±12 vs. 11±11 ng/ml, respectively, p≤0.001). Δ25D was higher with efavirenz or nevirapine compared to protease inhibitor based treatment (22±12, 27±17, vs. 13±10, respectively, p≤0.03).
conclusionsIn a pilot study in Botswana, 12-week high dose D₃ supplementation was safe and improved vitamin D, growth and HIV status; age and ART regimen were significant effect modifiers.
trial registrationClinicalTrials.gov NCT02189902.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.